Connect with us


Personal cancer treatment co OncoHost raises $ 35 million

The Israeli developer of personal cancer therapy OncoHost has announced the completion of an oversubscribed $ 35 million Series C funding round led by ALIVE Israel HealthTech VC with the participation of Leumi Partners, Menora Mivtachim, OurCrowd and other existing investors. ALIVE’s co-founder and managing partner Prof. Ari Shamiss has joined OncoHost’s Board of Directors.

The funding will be used to expand OncoHost’s ongoing multicenter PROPHETIC trial, which uses PROphet, the company’s machine learning-based host response profiling platform. The Binyamina-based company’s precision oncology diagnostic solution is expected to be launched commercially in the US in the third quarter of 2022.

Utilizing advanced proteomic analysis and AI-based host response science, OncoHost’s PROphet platform is a personal, real-time, dynamic ‘disease navigator’ that provides early identification of a person’s response to cancer treatment, analysis of treatment resistance mechanisms and potential available strategies to overcome this resistance . Results from clinical trials have shown that PROphet has a remarkably high accuracy in the assessment of non-small cell lung cancer (NSCLC) patient response after three months, six months and one year. Through one blood test pretreatment, the company’s multi-patented platform also provides clinicians with potential combination strategies to overcome treatment resistance.

Prof. Shamiss said: “OncoHost provides significant value to both cancer patients and their clinicians, and it is an honor to have led this transformative funding round. With promising and significant clinical results, OncoHost’s unique approach can create a brighter and better future for the world of precision oncology, maximization “of the likelihood of choosing the right therapy combinations and dramatically improving therapeutic outcomes for cancer patients. We are confident that Oncohost is poised to become a leading market leader in personal oncology proteomics.”

OncoHost’s CEO Dr. Ofer Sharon added: “This is OncoHost’s third and most significant investment round to date, demonstrating the company’s maturity, credibility and scalability. We are honored to be supported by leading local and global investment funds that understand and support our vision of changing the oncology landscape to a truly personal approach and want to be part of our journey to revolutionize cancer treatment. “

OncoHost continues to open additional clinical trial sites around the world and will expand its research into additional cancer indications.

Published by Globes, Israel business news – – on May 11, 2022.

© Copyright by Globes Publisher Itonut (1983) Ltd., 2022.

Click to comment

Leave a Reply

Your email address will not be published.